Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_assertion type Assertion NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_head.
- NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_assertion description "[A total of 143 genetic polymorphisms in 13 candidate genes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, ALDH1A1, ALDH3A1, GSTA1, GSTM1, GSTP1, GSTT1, ABCC2 and ABCC4), possibly involved in the activation, metabolism and transport of CPA, were genotyped using 184 cases who developed either > or =grade 3 leukopenia/neutropenia or > or =grade 2 gastrointestinal toxicity and 219 controls who did not show any ADRs throughout the treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_provenance.
- NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_assertion evidence source_evidence_literature NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_provenance.
- NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_assertion SIO_000772 19696793 NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_provenance.
- NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_assertion wasDerivedFrom befree-20140225 NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_provenance.
- NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_assertion wasGeneratedBy ECO_0000203 NP590098.RAFk-TVv34d_whhMXEz21Nt4fyVlW9h_y1QjPFFxN0CAY130_provenance.